New Tool: ProSource
Checkout our packaging and processing solutions finder.
Start Your Search

This Drug Shrank Cancer in 80% of Patients

A clinical trial at the University of Michigan showed promise for oral drug zanubrutinib to combat a specific type of lymphoma.

Download

A recent SciTechDaily article discussed a promising new study out of the University of Michigan that could change the way we treat lymphoma. The oral drug zanubrutinib was used to combat a specific type of slow-growing cancer known as marginal zone lymphoma. Results showed that the drug shrank cancer in 80% of the 20 subjects, with a fifth of them going into complete remission.

Zanubrutinib is a novel drug known as a Bruton Tyrosine Kinase inhibitor that blocks a specific enzyme that allows lymphomas to survive and grow. The clinical trial’s  results combined with a secondary study gained the drug FDA approval on a contingent basis for adults with that specific lymphoma that has otherwise been treated unsuccessfully.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub